https://www.optimumcomms.com/wp-content/uploads/2023/02/ASCEneuron_Logo_300px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-03-06 08:41:032024-03-06 08:41:03Asceneuron Expands Scientific Advisory Board with World Leading Experts in Neurodegenerative Diseases
https://www.optimumcomms.com/wp-content/uploads/2023/02/ASCEneuron_Logo_300px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-03-06 08:41:032024-03-06 08:41:03Asceneuron Expands Scientific Advisory Board with World Leading Experts in Neurodegenerative Diseases
https://www.optimumcomms.com/wp-content/uploads/2024/03/Heidelberg_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-03-06 08:35:482024-03-06 08:35:48Heidelberg Pharma to Present First Efficacy Data on HDP-101 and Data from Proprietary ADC Technology Platform at AACR Meeting 2024
https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-03-05 16:19:392024-03-05 16:19:39Novo Holdings Venture Investments 2023 Newsletter: A record year advancing innovative therapies for patients
https://www.optimumcomms.com/wp-content/uploads/2024/03/LinkedIn-Logo.jpg
200
200
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-03-05 11:02:472024-03-05 11:02:47Fibrocor Therapeutics enters into research and development collaboration with McQuade Center for Strategic Research and Development to advance Alport Syndrome program
https://www.optimumcomms.com/wp-content/uploads/2023/02/AMSilk_Logo_300px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-03-05 08:39:412024-03-05 08:39:41Collaboration between BRAIN Biotech and AMSilk: Protein engineering successfully improves structural proteins for performance materials
https://www.optimumcomms.com/wp-content/uploads/2023/02/Ariceum_Logo_300x180px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-03-05 08:38:282024-03-05 08:38:28Ariceum Therapeutics announces opening of new state-of-the-art laboratory in Berlin providing infrastructure for radiopharmaceutical development activities
https://www.optimumcomms.com/wp-content/uploads/2024/03/Heidelberg_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-03-04 12:00:572024-03-05 12:36:15Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million
https://www.optimumcomms.com/wp-content/uploads/2023/08/4SC_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-03-01 09:20:032024-03-01 09:20:034SC Files Marketing Authorisation Application with EMA for Resminostat (Kinselby)
https://www.optimumcomms.com/wp-content/uploads/2023/02/Ariceum_Logo_300x180px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-02-29 08:47:152024-02-29 08:47:15Ariceum Therapeutics Granted UK Authorisation to Conduct Phase I Clinical Study of its First-in-Class Iodine-123 Labelled PARP Inhibitor in Patients with Recurrent Glioblastoma
https://www.optimumcomms.com/wp-content/uploads/2023/02/Neuraxpharm_Logo_300px-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-02-29 08:44:212024-02-29 08:44:21Rare Disease Day 2024 – Call for greater awareness of X-linked adrenoleukodystrophy and cerebral adrenoleukodystrophy
https://www.optimumcomms.com/wp-content/uploads/2024/02/Bionical_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-02-29 08:34:562024-02-29 15:12:56Bionical Solutions Appoints Chief Technology Officer to Create Innovative Data Products and Software for the Digital Business
https://www.optimumcomms.com/wp-content/uploads/2023/08/Bioinnovation_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-02-29 08:19:122024-02-29 08:20:00BII welcomes twelve new companies to its Venture Lab program
https://www.optimumcomms.com/wp-content/uploads/2023/02/CurveTx_Logo_300x180px-80x80-Recovered.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-02-27 08:28:062024-02-27 08:28:06Curve Therapeutics raises £40.5 million to turbocharge discovery platform and advance breakthrough pipeline
https://www.optimumcomms.com/wp-content/uploads/2023/02/Neuraxpharm_Logo_300px-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-02-26 12:25:442024-02-26 12:25:44Neuraxpharm announces the first launch of BRIUMVI® (ublituximab) in Europe for the treatment of relapsing multiple sclerosis
https://www.optimumcomms.com/wp-content/uploads/2024/02/Kling_Bio_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-02-22 14:55:152024-02-23 08:55:54Kling Biotherapeutics to Present Discoveries on its Primary B-Cell Screening Platform at the ESMO Targeted Anticancer Therapies Congress
https://www.optimumcomms.com/wp-content/uploads/2023/02/StormTx_Logo_300-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-02-22 08:45:112024-02-22 08:45:11STORM Therapeutics to Present Findings on its First-in-Class METTL1 tRNA Methyltransferase Inhibitors at ESMO Targeted Anticancer Therapies CongressWe’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
